作者：Ammer E, Nietzsche S, Rien C, Kühnl A, Mader T, Heller R, Sauerbrei A, Henke A.
【摘自】医学微生物免疫学杂志， 2015年第204卷6期。
【文献摘要】
抑制代谢途径的药物不仅可以减少人类糖尿病诱导的疾病风险,同时也可能阻碍病毒病原体的复制。为了研究美国食品和药物管理局批准的抗肥胖药物奥利司他对不同人类致病病毒的抗病毒活性,作者进行了几个抗病毒研究、电镜分析以及脂肪酸吸收实验。结果表明，非细胞毒性浓度的奥利司他减少了柯萨奇病毒B3(CVB3)在不同的细胞类型的复制。此外,奥利司他还显示出了细胞保护作用，并可以改变存在于柯萨奇B3病毒感染细胞中的病毒复制所必须的多层结构的形成。奥利司他能通过对根皮素的管理降低从细胞外环境中吸收脂肪酸，从而在一定程度上影响柯萨奇B3病毒的复制；最后，奥利司他可显著降低水痘-带状疱疹病毒的复制。
【文献原文】
The anti-obesity drug orlistat reveals anti-viral activity.
Author: Ammer E1, Nietzsche S2, Rien C1, Kühnl A1, Mader T1, Heller R3, Sauerbrei A1, Henke A4.
Author information：
1Institute of Virology and Antiviral Therapy, Jena University Hospital, Friedrich Schiller University Jena, Hans-Knöll-Str. 2, 07745, Jena, Germany.
2Center of Electron Microscopy, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany.
3Institute for Molecular Cell Biology, Center for Molecular Biomedicine, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany.
4Institute of Virology and Antiviral Therapy, Jena University Hospital, Friedrich Schiller University Jena, Hans-Knöll-Str. 2, 07745, Jena, Germany.
Quote From: Med Microbiol Immunol. 2015 Dec;204(6):635-45.
【ABSTRACT】
The administration of drugs to inhibit metabolic pathways not only reduces the risk of obesity-induced diseases in humans but may also hamper the replication of different viral pathogens. In order to investigate the value of the US Food and Drug Administration-approved anti-obesity drug orlistat in view of its anti-viral activity against different human-pathogenic viruses, several anti-viral studies, electron microscopy analyses as well as fatty acid uptake experiments were performed. The results indicate that administrations of non-cytotoxic concentrations of orlistat reduced the replication of coxsackievirus B3 (CVB3) in different cell types significantly. Moreover, orlistat revealed cell protective effects and modified the formation of multi-layered structures in CVB3-infected cells, which are necessary for viral replication. Lowering fatty acid uptake from the extracellular environment by phloretin administrations had only marginal impact on CVB3 replication. Finally, orlistat reduced also the replication of varicella-zoster virus moderately but had no significant influence on the replication of influenza A viruses. The data support further experiments into the value of orlistat as an inhibitor of the fatty acid synthase to develop new anti-viral compounds, which are based on the modulation of cellular metabolic pathways.
文献详情：http://www.ncbi.nlm.nih.gov/pubmed/?term=The+anti-obesity+drug+orlistat+reveals+anti-viral+activity